journal article·2021-08-04

Coordination Compounds As Multi-Delivery Systems for Osteoporosis

Jéssica S. Barbosa, Miguel Pinto, Sandra Barreiro, Carlos Fernandes, Ricardo F. Mendes, Pedro Lavrador, Vítor M. Gaspar, João F. Mano, Fernanda Borges, Fernando Remião, Susana S. Braga, Filipe A. Almeida Paz

ACS Applied Materials & Interfaces· Volume 13· Issue 30
Publisher page

Abstract

Osteoporosis therapies leveraging bisphosphonates and mineral components (e.g., magnesium, calcium, and strontium) have been raising attention because of their potential for managing this ever-growing disease. The administration of multicomponent therapeutics (combined therapy) in elderly patients is complex and suffers from low patient adherence. Herein, we report an all-in-one combination of four antiosteoporotic components into a new family of coordination complexes: [M2(H4alen)4(H2O)2]·1.5H2O [where M2+ = Mg2+ (1), (Mg0.535Ca0.465)2+ (2) and (Mg0.505Ca0.450Sr0.045)2+ (3)]. These solid-state complexes were prepared, for the first time, through microwave-assisted synthesis. It is demonstrated that the compounds are capable of releasing their antiosteoporotic components, both in conditions that mimic the path along the gastrointestinal tract and in long periods under physiological conditions (pH ∼7.4). More importantly, when administered in low concentrations, the compounds did not elicit a cytotoxic effect toward liver, kidney, and osteoblast-like cell lines. Besides, it is important to highlight the unique coordination complex with four bone therapeutic components, [(Mg0.505Ca0.450Sr0.045)2(H4alen)4(H2O)2]·1.5H2O (3), which significantly promoted osteoblast metabolic activity up to ca. 1.4-fold versus the control group. These findings bring this type of compounds one-step closer to be considered as an all-in-one and more effective treatment for managing chronic bone diseases, prompting further research on their therapeutic properties.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone health and treatments · Chemical Synthesis and Characterization · Medical Imaging and Pathology Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CICECO−Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal

LAQV−REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal

CIQUP, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal

UCIBIO-REQUIMTE, Laboratory of Toxicology, Biological Sciences Department, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

Funding

Fundação para a Ciência e a Tecnologia

References (55)

Show source-provided references
1. 10.1016/j.beem.2008.06.00110.1016/j.beem.2008.06.001 ↗
2. Seibel M. J. · Clinical biochemist. Reviews/Australian Association of Clinical Biochemists · 2005 · 26 · 97
3. 10.1007/s11657-013-0136-110.1007/s11657-013-0136-1 ↗
4. 10.1126/science.289.5484.150410.1126/science.289.5484.1504 ↗
5. 10.1093/oxfordjournals.epirev.a03628110.1093/oxfordjournals.epirev.a036281 ↗
6. 10.1016/8756-3282(95)00258-410.1016/8756-3282(95)00258-4 ↗
7. Health U. D. o. · 2004 · 87
8. Business Wire, Inc, 2020. https://www.researchandmarkets.com/reports/4857727/osteoporosis-drugs-market-by-drug-class?utm_source=dynamic&utm_medium=BW&utm_code=45n3xt&utm_campaign=1322201+-+Global+Osteoporosis+Drugs+Market+Expected+to+Grow+with+a+CAGR+of+4.3%25+During+the+Forecast+Period%2c+2019-2025&utm_exec=anwr281bwd (accessed Jan 27, 2021).
9. Fior Market Research LLP. https://www.globenewswire.com/news-release/2019/08/29/1908233/0/en/Global-Osteoporosis-Drugs-Market-is-Expected-to-Reach-USD-1-82-Billion-by-2025-Fior-Markets.html (accessed Jan 27, 2021).
10. 10.1056/NEJM20010510344190410.1056/NEJM200105103441904 ↗
11. 10.2147/DDDT.S3150410.2147/DDDT.S31504 ↗
12. 10.1111/j.1753-4887.1995.tb01505.x10.1111/j.1753-4887.1995.tb01505.x ↗
13. Stending-Lindberg G. · Magnesium Research · 1993 · 6 · 155
14. 10.1056/NEJM19911024325170110.1056/NEJM199110243251701 ↗
15. 10.1056/NEJM19930218328070210.1056/NEJM199302183280702 ↗
16. 10.1016/j.actbio.2009.12.04110.1016/j.actbio.2009.12.041 ↗
17. 10.1016/j.bone.2004.04.02610.1016/j.bone.2004.04.026 ↗
18. 10.1016/j.biomaterials.2010.01.12110.1016/j.biomaterials.2010.01.121 ↗
19. 10.1016/j.ceramint.2018.06.00910.1016/j.ceramint.2018.06.009 ↗
20. 10.1177/1759720X1348318710.1177/1759720X13483187 ↗
21. 10.1210/jc.2012-304810.1210/jc.2012-3048 ↗
22. 10.1056/NEJM19900927323130510.1056/NEJM199009273231305 ↗
23. 10.1056/NEJM19920709327020410.1056/NEJM199207093270204 ↗
24. 10.1016/j.biomaterials.2014.03.06910.1016/j.biomaterials.2014.03.069 ↗
25. 10.1021/acs.inorgchem.5b0163410.1021/acs.inorgchem.5b01634 ↗
26. 10.1021/acsami.9b1100410.1021/acsami.9b11004 ↗
27. 10.1002/adma.20130112910.1002/adma.201301129 ↗
28. 10.1039/D0CC00439A10.1039/D0CC00439A ↗
29. 10.1039/C9TB01857C10.1039/C9TB01857C ↗
30. 10.1107/S002188989300201810.1107/S0021889893002018 ↗
31. 2005
32. 1997
33. 10.1107/S160057671402298510.1107/S1600576714022985 ↗
34. 10.1107/S205327331402637010.1107/S2053273314026370 ↗
35. 10.1107/S205322961402421810.1107/S2053229614024218 ↗
36. 10.1107/S002188981104320210.1107/S0021889811043202 ↗
37. 10.1016/j.ejmech.2019.01.05510.1016/j.ejmech.2019.01.055 ↗
38. 10.1039/C9DT04211C10.1039/C9DT04211C ↗
39. 10.1021/acsami.8b1722410.1021/acsami.8b17224 ↗
40. 10.1021/acs.bioconjchem.8b0015110.1021/acs.bioconjchem.8b00151 ↗
41. 10.1021/acs.bioconjchem.8b0038310.1021/acs.bioconjchem.8b00383 ↗
42. 10.1136/gut.29.8.103510.1136/gut.29.8.1035 ↗
43. 10.1016/j.nano.2017.08.01110.1016/j.nano.2017.08.011 ↗
44. 10.1186/1471-2369-14-9610.1186/1471-2369-14-96 ↗
45. 10.1056/NEJM20000803343051210.1056/NEJM200008033430512 ↗
46. Carrere C. · Gastroenterol. Clin. Biol. · 2002 · 26 · 179
47. 10.1007/s00198-007-0323-210.1007/s00198-007-0323-2 ↗
48. 10.1016/j.ejmech.2019.11177010.1016/j.ejmech.2019.111770 ↗
49. 10.1016/j.tripleo.2008.03.03610.1016/j.tripleo.2008.03.036 ↗
50. 10.1016/j.biomaterials.2003.09.00110.1016/j.biomaterials.2003.09.001 ↗
51. 10.1016/j.ijpharm.2018.11.02310.1016/j.ijpharm.2018.11.023 ↗
52. 10.1002/jbm.a.3197510.1002/jbm.a.31975 ↗
53. 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.0.CO;2-A10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.0.CO;2-A ↗
54. 10.1080/21691401.2018.148108110.1080/21691401.2018.1481081 ↗
55. 10.1021/acs.jmedchem.0c0129210.1021/acs.jmedchem.0c01292 ↗